Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN005T long-term follow-up of AllerT in birch pollen allergy
2013-003881-15Phase 2Terminated
- Sponsor
- Anergis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetirizine in birch pollen allergy and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Anergis. Primary endpoint: Average combined Rhinoconjunctivitis Symptom and Medication Score. Started Nov 2013; status: terminated.
02
Drugs
cetirizine
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2013-003881-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003881-15.